Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

nebicapone

Known as: 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Acetophenones

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.
To determine the efficacy, safety and tolerability of nebicapone, a new catechol-O-methyltransferase inhibitor for the treatment… Expand
Is this relevant?
2010
2010
Chronopharmacology of nebicapone, a new catechol-O-methyltransferase inhibitor.
OBJECTIVE To investigate the chronopharmacology of nebicapone, a new catechol-O-methyltransferase (COMT) inhibitor currently… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
Review
2010
Review
2010
Toxicology and safety of COMT inhibitors.
The development of catechol-O-methyltransferase (COMT) inhibitors for the adjunct treatment to levodopa and aromatic L-amino acid… Expand
  • table I
  • figure 1
  • table II
  • figure 2
  • table III
Is this relevant?
Review
2010
Review
2010
Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
Entacapone and tolcapone are reversible COMT inhibitors which have been approved for clinical use in patients with Parkinson… Expand
Is this relevant?
2009
2009
Species differences in pharmacokinetic and pharmacodynamic properties of nebicapone.
The present study was designed to characterize pharmacodynamic and pharmacokinetic properties of nebicapone in rats and mice… Expand
Is this relevant?
2009
2009
Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover…
BACKGROUND Nebicapone is a reversible catechol-O-methyltransferase (COMT) inhibitor. Coadministration of a COMT inhibitor with… Expand
  • figure 1
  • figure 2
  • table II
  • figure 3
  • table III
Is this relevant?
2008
2008
Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
OBJECTIVE To investigate the effects of nebicapone, a new catechol-O-methyltransferase (COMT) inhibitor, on levodopa… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2008
2008
Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects
ObjectiveNebicapone is a new catechol-O-methyltransferase inhibitor. In vitro, nebicapone has showed an inhibitory effect upon… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
2006
2006
Human metabolism of nebicapone (BIA 3-202), a novel catechol-o-methyltransferase inhibitor: characterization of in vitro glucuronidation.
Nebicapone (BIA 3-202; 1-[3,4-dihydroxy-5-nitrophenyl]-2-phenylethanone), a novel catechol-O-methyltransferase inhibitor, is… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2002
2002
Chemical synthesis and characterization of conjugates of a novel catechol-O-methyltransferase inhibitor.
BIA 3-202, 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone 3, is a novel, reversible, and tight-binding peripheral inhibitor of… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE